secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001558370-23-017624
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn remains under FDA clinical hold; seeks authorized share increase for viability
--------------------------------------------------------------------------------

- FDA partial clinical hold still unresolved; comprehensive resubmission made, outcome pending.
- Workforce reductions implemented; cash burn rate and operating expenses cut to conserve resources.
- Amarex arbitration final hearing scheduled for August 12, 2024; Sidley Austin LLP retained.
- Developed MASH clinical trial protocol and AI partnership for longer-acting therapeutic.
- Shareholders asked to approve increase in authorized common shares at Nov 9 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023017624/0001558370-23-017624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023017624/cydy-20231103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer